Jilin Province Huinan Changlong Bio-pharmacy Company Limited engages in the manufacture and distribution of Chinese medicines and pharmaceutical products in the People’s Republic of China. More Details
Flawless balance sheet and undervalued.
Share Price & News
How has Jilin Province Huinan Changlong Bio-pharmacy's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 8049 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 8049's weekly volatility (6%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 8049 underperformed the Hong Kong Pharmaceuticals industry which returned 18.8% over the past year.
Return vs Market: 8049 underperformed the Hong Kong Market which returned 28% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Jilin Province Huinan Changlong Bio-pharmacy's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StIf You Had Bought Jilin Province Huinan Changlong Bio-pharmacy's (HKG:8049) Shares Five Years Ago You Would Be Down 37%
4 months ago | Simply Wall StHow Is Jilin Province Huinan Changlong Bio-pharmacy's (HKG:8049) CEO Paid Relative To Peers?
6 months ago | Simply Wall StWhat Is The Ownership Structure Like For Jilin Province Huinan Changlong Bio-pharmacy Company Limited (HKG:8049)?
Is Jilin Province Huinan Changlong Bio-pharmacy undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 8049 (HK$1.25) is trading below our estimate of fair value (HK$5.01)
Significantly Below Fair Value: 8049 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 8049 is good value based on its PE Ratio (4.6x) compared to the HK Pharmaceuticals industry average (12.6x).
PE vs Market: 8049 is good value based on its PE Ratio (4.6x) compared to the Hong Kong market (11.8x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 8049's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 8049 is good value based on its PB Ratio (0.4x) compared to the HK Pharmaceuticals industry average (1.3x).
How is Jilin Province Huinan Changlong Bio-pharmacy forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jilin Province Huinan Changlong Bio-pharmacy has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Jilin Province Huinan Changlong Bio-pharmacy performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 8049 has high quality earnings.
Growing Profit Margin: 8049's current net profit margins (20.3%) are lower than last year (22.4%).
Past Earnings Growth Analysis
Earnings Trend: 8049's earnings have grown by 3% per year over the past 5 years.
Accelerating Growth: 8049's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 8049 had negative earnings growth (-12.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (2.7%).
Return on Equity
High ROE: 8049's Return on Equity (9.4%) is considered low.
How is Jilin Province Huinan Changlong Bio-pharmacy's financial position?
Financial Position Analysis
Short Term Liabilities: 8049's short term assets (CN¥807.9M) exceed its short term liabilities (CN¥415.4M).
Long Term Liabilities: 8049's short term assets (CN¥807.9M) exceed its long term liabilities (CN¥43.6M).
Debt to Equity History and Analysis
Debt Level: 8049's debt to equity ratio (0.03%) is considered satisfactory.
Reducing Debt: 8049's debt to equity ratio has reduced from 1% to 0.03% over the past 5 years.
Debt Coverage: 8049's debt is well covered by operating cash flow (37806.8%).
Interest Coverage: 8049 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Jilin Province Huinan Changlong Bio-pharmacy current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 8049's dividend (3.34%) is higher than the bottom 25% of dividend payers in the Hong Kong market (1.93%).
High Dividend: 8049's dividend (3.34%) is low compared to the top 25% of dividend payers in the Hong Kong market (5.97%).
Stability and Growth of Payments
Stable Dividend: 8049 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 8049 has only been paying a dividend for 2 years, and since then payments have fallen.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Hong Zhang (65 yo)
Mr. Hong Zhang serves as the Chief Executive Officer and Compliance Officer at Jilin Province Huinan Changlong Bio-pharmacy Co. Ltd. and has been its Executive Chairman since October 1989. Mr. Zhang is res...
CEO Compensation Analysis
Compensation vs Market: Hong's total compensation ($USD80.67K) is below average for companies of similar size in the Hong Kong market ($USD227.72K).
Compensation vs Earnings: Hong's compensation has been consistent with company performance over the past year.
Experienced Management: 8049's management team is seasoned and experienced (13 years average tenure).
Experienced Board: 8049's board of directors are considered experienced (5.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Jilin Province Huinan Changlong Bio-pharmacy Company Limited's company bio, employee growth, exchange listings and data sources
- Name: Jilin Province Huinan Changlong Bio-pharmacy Company Limited
- Ticker: 8049
- Exchange: SEHK
- Founded: 1989
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$700.314m
- Shares outstanding: 560.25m
- Website: https://www.jlchanglong.com
Number of Employees
- Jilin Province Huinan Changlong Bio-pharmacy Company Limited
- 31 Beishan Street
- Pharmaceutical Industrial Park
- Jilin Province
Jilin Province Huinan Changlong Bio-pharmacy Company Limited engages in the manufacture and distribution of Chinese medicines and pharmaceutical products in the People’s Republic of China. It offers tablet...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/17 10:20|
|End of Day Share Price||2021/04/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.